Abbott Laboratories logo
Abbott Laboratories (ABT)
Compare

Abbott Laboratories (ABT) Debt to Equity Ratio: 0.29

Is Abbott Laboratories’s debt to equity ratio high or low?

Abbott Laboratories's debt to equity ratio of 0.29 is 35% below its 5-year average of 0.44, near the low end of its 5-year range (0.29–0.61).

As of Thursday, June 18, 2026. 4.92% below its 12-month average of 0.30.

ABT Debt to Equity Ratio Chart

ABT Debt to Equity Ratio
0.29-9.38% 1Y
Zoom

ABT Average Debt to Equity Ratio Chart

ABT Current vs Average Debt to Equity Ratio Chart

ABT Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

0.29

DEBT TO EQUITY RATIO AVG TTM

0.30

DEBT TO EQUITY RATIO AVG 3Y

0.38

DEBT TO EQUITY RATIO AVG 5Y

0.44

DEBT TO EQUITY RATIO AVG 10Y

0.57

DEBT TO EQUITY RATIO AVG 15Y

0.57

DEBT TO EQUITY RATIO AVG 20Y

0.60

CURRENT VS TTM AVG

-4.92%

CURRENT VS 3Y AVG

-23.18%

CURRENT VS 5Y AVG

-34.59%

CURRENT VS 10Y AVG

-49.37%

CURRENT VS 15Y AVG

-49.29%

CURRENT VS 20Y AVG

-51.44%

ABT Competitors' Debt to Equity Ratio

NAMEMARKET CAPDEBT TO EQUITY RATIOTTM3Y5Y
Abbott Laboratories (ABT)$154.08B0.290.300.380.44
Gilead Sciences, Inc. (GILD)vs ›$155.75B1.081.231.191.29
Pfizer Inc. (PFE)vs ›$147.73B0.780.770.680.63
Intuitive Surgical, Inc. (ISRG)vs ›$142.44B0.020.010.010.01
Thermo Fisher Scientific Inc. (TMO)vs ›$171.57B0.760.710.760.76
CVS Health Corporation (CVS)vs ›$126.52B1.241.171.091.10
Danaher Corporation (DHR)vs ›$125.88B0.350.350.370.43
Amgen Inc. (AMGN)vs ›$184.40B6.318.279.397.67
Stryker Corporation (SYK)vs ›$119.03B0.730.710.740.82
Novo Nordisk A/S (NVO)vs ›$191.59B0.670.700.490.42

Financial Health

Debt/Equity

0.29

Current Ratio

1.58

Abbott Laboratories Debt to Equity Ratio Formula & Definition

Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Abbott Laboratories Debt to Equity Ratio FAQ

What is the debt to equity ratio for Abbott Laboratories (ABT)?
The debt to equity ratio for ABT stock is 0.29.
Is Abbott Laboratories's debt to equity ratio high or low?
Abbott Laboratories's debt to equity ratio of 0.29 is 35% below its 5-year average of 0.44, near the low end of its 5-year range (0.29–0.61).
What is the TTM average debt to equity ratio for Abbott Laboratories (ABT)?
The TTM average debt to equity ratio for ABT stock is 0.30.
What is the 3Y average debt to equity ratio for Abbott Laboratories (ABT)?
The 3Y average debt to equity ratio for ABT stock is 0.38.
What is the 5Y average debt to equity ratio for Abbott Laboratories (ABT)?
The 5Y average debt to equity ratio for ABT stock is 0.44.
What is the 10Y average debt to equity ratio for Abbott Laboratories (ABT)?
The 10Y average debt to equity ratio for ABT stock is 0.57.
What is the 15Y average debt to equity ratio for Abbott Laboratories (ABT)?
The 15Y average debt to equity ratio for ABT stock is 0.57.
What is the 20Y average debt to equity ratio for Abbott Laboratories (ABT)?
The 20Y average debt to equity ratio for ABT stock is 0.60.

Abbott Laboratories Debt to Equity Ratio History

DATEDEBT TO EQUITY RATIO
2025-12-310.29
2024-12-310.32
2023-12-310.41
2022-12-310.49
2021-12-310.54
2020-12-310.61
2019-12-310.61
2018-12-310.64
2017-12-310.90
2016-12-311.07
2015-12-310.42
2014-12-310.36
2013-12-310.26
2012-12-310.77
2011-12-310.63
2010-12-310.83
2009-12-310.71
2008-12-310.65
2007-12-310.69
2006-12-310.88
2005-12-310.46
2004-12-310.47
2003-12-310.46
2002-12-310.60
2001-12-310.80
2000-12-310.18
1999-12-310.30
1998-12-310.54
1997-12-310.54
1996-12-310.48

About Abbott Laboratories

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Abbott Park, IL
114,000 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Robert Ford